New cancer clinical trial: Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer

Published on: April 26, 2018 at 12:00PM
Condition:   Advanced Pancreatic Cancer
Interventions:   Biological: Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer;   Procedure: cryotherapy
Sponsors:   Fuda Cancer Hospital, Guangzhou;   Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
Recruiting
https://ift.tt/2Hw6GV4